Mucopolysaccharidosis I Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2023 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Mucopolysaccharidosis I Clinical Trials Market Report Overview
The Mucopolysaccharidosis I clinical trial market research report provides an overview of the Mucopolysaccharidosis I clinical trials scenario. The report provides top-line data relating to the clinical trials on Mucopolysaccharidosis I. It also includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. Moreover, it offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status, and sponsor type.
Key Regions | North America, Europe, Asia-Pacific, Middle East & Africa, and South & Central America |
Key Countries | The US, the United Kingdom, Brazil, Germany, Italy, Canada, Japan, Netherlands, Russia, and Australia |
Key Sponsor Types | Institution, Company, and Government |
Leading Sponsors | Sanofi, JCR Pharmaceuticals Co Ltd, BioMarin/Genzyme LLC, Sangamo Therapeutics Inc, BioMarin Pharmaceutical Inc, Eloxx Pharmaceuticals Inc, Altasciences Co Inc, Medpace Holdings Inc, Magenta Therapeutics Inc, and Jupiter Neurosciences Inc |
Mucopolysaccharidosis I Clinical Trials Market Segmentation by Regions and Countries
The key regions in the Mucopolysaccharidosis I clinical trials market are North America, Europe, Asia-Pacific, Middle East & Africa, and South & Central America among others. As of April 2023, the majority of the clinical trials were conducted in North America.
The US, the United Kingdom, Brazil, Germany, Italy, Canada, Japan, Netherlands, Russia, and Australia are some of the key countries in the Mucopolysaccharidosis I clinical trials market. In the country-wise analysis, the US has the highest number of Mucopolysaccharidosis I clinical trials, as of April 2023, followed by the UK and Brazil.
G7 countries: Among the G7 (United States, United Kingdom, Germany, France, Italy, Canada, and Japan) countries, the US has the highest proportion of Mucopolysaccharidosis I to Metabolic Disorders clinical trials as of April 2023.
E7 countries: Among the E7 (Brazil, Russia, India, China, Mexico, Turkey, and Indonesia) countries, Brazil has the highest proportion of Mucopolysaccharidosis I to Metabolic Disorders clinical trials as of April 2023.
Mucopolysaccharidosis I Clinical Trials Analysis by Regions, 2023 (%) For more regional insights into the Mucopolysaccharidosis I clinical trials market, download a free report sample
Mucopolysaccharidosis I Clinical Trials Market Segmentation by Sponsor Types
The key sponsor types in the Mucopolysaccharidosis I clinical trials market are institution, company, and the government. Out of them, the company sponsor type dominates the market.
Mucopolysaccharidosis I Clinical Trials Market Analysis by Sponsor Types, 2023 (%) For more sponsor type insights into the Mucopolysaccharidosis I clinical trials market, download a free report sample
Mucopolysaccharidosis I Clinical Trials Market - Competitive Landscape
The leading sponsors in the Mucopolysaccharidosis I clinical trials market are Sanofi, JCR Pharmaceuticals Co Ltd, BioMarin/Genzyme LLC, Sangamo Therapeutics Inc, BioMarin Pharmaceutical Inc, Eloxx Pharmaceuticals Inc, Altasciences Co Inc, Medpace Holdings Inc, Magenta Therapeutics Inc, and Jupiter Neurosciences Inc among others. As of April 2023, Sanofi sponsored the highest number of Mucopolysaccharidosis I trials.
Mucopolysaccharidosis I Clinical Trials Market Analysis by Sponsors, 2023 (%)
To know more about the leading players in the Mucopolysaccharidosis I clinical trials market, download a free report sample
Segments Covered in the Report
Mucopolysaccharidosis I Clinical Trials Regional Outlook (2023)
- Asia-Pacific
- North America
- Europe
- Middle East & Africa
- South & Central America
Mucopolysaccharidosis I Clinical Trials Country Outlook (2023)
- The US
- United Kingdom
- Brazil
- Germany
- Italy
- Canada
- Japan
- Netherlands
- Russia
- Australia
Mucopolysaccharidosis I Clinical Trials Sponsor Type Outlook (2023)
- Institution
- Company
- Government
Scope
- The report provides a snapshot of the global clinical trials landscape
- The report provides top-level data related to the clinical trials by region, country (G7 & E7), trial status, trial phase, sponsor type, and end-point status
- The report reviews the top companies involved and enlists all trials (trial title, phase, and status) pertaining to the company
- The report provides all the unaccomplished trials (terminated, suspended, and withdrawn) with reasons for unaccomplishment
- The report provides enrollment trends for the past five years
- The report provides the latest news for the past three months
Reasons to Buy
- Assists in formulating key business strategies regarding investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top-level analysis of the global clinical trials market which helps in identifying key business opportunities
- Supports understanding of trial count and enrollment trends by country in the global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended, or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional, and country level
JCR Pharmaceuticals Co Ltd
BioMarin/Genzyme LLC
BioMarin Pharmaceutical Inc
Sangamo Therapeutics Inc
Altasciences Co Inc
Eloxx Pharmaceuticals Inc
Magenta Therapeutics Inc
Medpace Holdings Inc
Jupiter Neurosciences Inc
Table of Contents
Table
Figures
Frequently asked questions
-
Which region held the highest Mucopolysaccharidosis I clinical trials market share?
North America held the highest Mucopolysaccharidosis I clinical trials market share.
-
Which country accounted for the largest Mucopolysaccharidosis I clinical trials market size?
The US accounted for the largest Mucopolysaccharidosis I clinical trials market size.
-
What are the key sponsor types in the Mucopolysaccharidosis I clinical trials market?
As of April 2023, most of the trials have been sponsored by company followed by institution.
-
Who was the leading sponsor in the Mucopolysaccharidosis I clinical trials market?
As of April 2023, Sanofi sponsored the highest number of mucopolysaccharidosis i (mps i) (hurler syndrome ) clinical trials.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.